← Back to patent-cliff list
Meglumine Sodium Succinate
Tier C — Watch / tradeMeglumine Sodium Succinate
Polysan Scientific & Technological Pharmaceutical Company
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Brand：Eeamberin
Indications (approved)：糖尿病酮症酸中毒, 酸中毒
Regional status
US
-
EU
Phase III
2025-05-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Meglumine Sodium Succinate?
Approved indications include: 糖尿病酮症酸中毒, 酸中毒.
When does the Meglumine Sodium Succinate patent expire?
No public expiry year is available for Meglumine Sodium Succinate yet; this page updates once verified.
How do I get a quote for Meglumine Sodium Succinate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30